Boffins Discover Novel Marker for Alzheimer's Disease

A previously unknown substance in spinal fluid- a beta-amyloid protein called Abeta16-could be used as a marker to diagnose Alzheimer's disease, say Gothenburg researchers.

Gothenburg researchers now believe that a previously unknown substance in spinal fluid- a beta-amyloid protein called Abeta16-could be used as a marker to diagnose Alzheimer's disease.

The findings, described in a thesis from the Sahlgrenska Academy at the University of Gothenburg, Sweden, will also be useful in research into new medications.

Diseases Related to Old Age
Ageing is referred to the accumulation of changes that brings a person closer to death.

The researchers conducted two independent studies, and found that Alzheimer's patients have higher levels of the protein in their spinal fluid than do healthy individuals.

"The discovery of the new protein could be used to diagnose patients with Alzheimer's and also help determine which medications are most effective for the disease," said biochemist Erik Portelius, the author of the thesis.

Alzheimer's disease includes the formation of plaque on the brain. Neurons and other cell types form around 20 different beta-amyloid proteins, and these are excreted into the spinal fluid around the brain.

Risk Factors for Alzheimers Disease
Cognitively normal adults exhibiting atrophy of their temporal lobe or damage to blood vessels in the brain are more likely to develop Alzheimer’s disease.

"These types of beta-amyloid proteins can be analysed with great precision, and our research team has also shown that the analyses can be used to distinguish between Alzheimer's patients and healthy individuals with a high degree of accuracy," said Portelius.

The beta-amyloid protein Abeta42, which is particularly prevalent in the plaque, is created when a larger protein is cut into pieces by certain enzymes.

Sugar variant may make a world of difference to Alzheimers disease
A novel study by Canadian researchers has revealed that variants of a sugar, is found to improve Alzheimers

The new Alzheimer's drugs, which are currently being tested, aim to reduce the production of Abeta42 by blocking these enzymes.

The researchers found that these drugs increase the level of the newly discovered Abeta16.

Killing two birds (cholesterol and Alzheimers disease) with the same stone
New study points at possible treatment of both cholesterol and Alzheimer’s disease

"Abeta42 and Abeta16 are formed from the same precursor molecule, but the enzymatic process is different and Abeta16 is not harmful. The finding that Abeta16 is a very sensitive biomarker for the effect of these drugs may become very useful in future treatment studies," said Portelius.

Source-ANI
TAN